Year in Review: Updates in Treating Myelofibrosis - Episode 4

Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib

,

Raajit K. Rampal, MD, PhD, discusses promising data on navtemadlin plus ruxolitinib for patients with myelofibrosis who had suboptimal responses to ruxolitinib, showing significant improvements in spleen and symptom responses, with further phase 3 studies anticipated.

EP. 1: How JAK Inhibitors Have Shaped the Landscape of MF
EP. 2: Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2
EP. 3: Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1
Now Viewing
EP. 4: Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib
EP. 5: Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034
EP. 6: Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001
EP. 7: Future Directions in Combination Therapies for Myelofibrosis
EP. 8: Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF
EP. 9: The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib
EP. 10: Selection and Sequencing of JAK Inhibitors for Patients With MF
EP. 11: Individualizing Therapy Goals for Patients With Myelofibrosis
EP. 12: Emerging Treatments for Myelofibrosis

Related Content:

Year in Review: Updates in Treating MyelofibrosisMyeloproliferative NeoplasmsHematologic Oncology
Ribaxamase Shows Safety in the Prevention of aGVHD Following Allo-HSCT
Dr Battiwalla on the Expanding Use of Bispecific Antibodies in NHL
Meta-Analysis Reveals Potential Role of Clonal Hematopoiesis on Allogeneic and Autologous HSCT Outcomes